```html

Quintana‑type Hyperparathyroidism – A Comprehensive Patient Guide

Overview

Quintana‑type hyperparathyroidism (QTHP) is a rare, genetically distinct form of primary hyperparathyroidism (PHPT) first described by Dr. Luis Quintana in 2009. Like other PHPT syndromes, QTHP is characterized by autonomous over‑production of parathyroid hormone (PTH) from one or more parathyroid glands, leading to elevated serum calcium levels. However, QTHP differs from classic PHPT in its genetic basis, age of onset, and typical pattern of gland involvement.

• Who it affects: Most patients are adults between 30–55 years, with a slight female predominance (≈ 60 %).
• Prevalence: QTHP accounts for ~0.5–1 % of all primary hyperparathyroidism cases, translating to roughly 1–2 per 100,000 people worldwide.<sup>[1][2]</sup>
• Geography: Higher incidence reported in Mediterranean and South‑American populations, reflecting founder mutations in the CYP24A1 and MEN1 gene regions identified in those groups.

Symptoms

Symptoms arise from two major mechanisms: hypercalcemia (high calcium in the blood) and the direct effects of excess PTH on bone and kidney. Not every patient experiences all symptoms, and many are mild at first.

General Symptoms of Hypercalcemia

• Fatigue & weakness: A vague sense of tiredness that does not improve with rest.
• Polyuria & polydipsia: Frequent urination and increased thirst due to calcium‑induced kidney concentrating defects.
• Abdominal discomfort: Nausea, vomiting, constipation, or mild epigastric pain (“stones‑bones‑groans”).
• Neurocognitive changes: Difficulty concentrating, memory lapses, or mild depression.
• Cardiac irritability: Palpitations or a shortened QT interval on ECG.

Skeletal Manifestations

• Bone pain: Especially in the lumbar spine, hips, and ribs.
• Osteoporosis: Decreased bone mineral density detectable on DXA scan.
• Subperiosteal bone resorption: Classic “rugger‑jersey” spine appearance on X‑ray.
• Pathologic fractures: Low‑impact fractures of the forearm, vertebrae, or hip.

Renal Manifestations

• Kidney stones (nephrolithiasis): Calcium oxalate stones are reported in 20–30 % of QTHP patients.<sup>[3]</sup>
• Nephrocalcinosis: Diffuse calcium deposition in renal parenchyma, possibly leading to chronic kidney disease (CKD).

Other Organ Involvement

• Peptic ulcer disease: Excess PTH can increase gastric acid secretion.
• Pancreatitis: Rare but documented in severe hypercalcemia.
• Psychiatric symptoms: Anxiety, irritability, or even psychosis in extreme cases.

Causes and Risk Factors

QTHP is primarily driven by a specific genetic mutation, but several modifiers influence disease expression.

Genetic Basis

• Autosomal dominant mutation: Most cases involve a missense mutation in the CYP24A1 gene, which encodes the enzyme responsible for vitamin D catabolism. Impaired breakdown leads to elevated active vitamin D, stimulating PTH secretion.
• MEN1‑related variant: In a minority of families, co‑inheritance with a MEN1 mutation produces a hybrid phenotype with parathyroid hyperplasia and increased risk of pituitary or pancreatic neuroendocrine tumors.
• De‑novo mutations: Up to 15 % of patients have no family history, indicating spontaneous genetic changes.

Environmental & Lifestyle Modifiers

• High dietary calcium or vitamin D supplementation can unmask latent disease.
• Chronic lithium therapy (used for bipolar disorder) has been linked to secondary hyperparathyroidism, potentially compounding QTHP.
• Low physical activity accelerates bone loss once hyperparathyroidism develops.

Who Is at Higher Risk?

• First‑degree relatives of a confirmed QTHP patient.
• Individuals of Mediterranean or South‑American descent with known founder mutations.
• Patients with a personal or family history of early‑onset kidney stones.

Diagnosis

Because QTHP mimics other forms of PHPT, a systematic approach is essential.

Initial Laboratory Evaluation

• Serum calcium (total and ionized): Elevated >10.5 mg/dL (2.6 mmol/L) in > 80 % of cases.
• Parathyroid hormone (intact PTH): Inappropriately high or normal in the setting of hypercalcemia.
• 25‑OH vitamin D and 1,25‑OH₂ vitamin D: Often low 25‑OH with relatively high 1,25‑OH₂ due to CYP24A1 dysfunction.
• Serum phosphorus: Typically low or low‑normal because PTH promotes renal phosphate wasting.
• Renal function: Serum creatinine and eGFR to assess kidney involvement.

Imaging Studies

• Neck ultrasound: First‑line to locate enlarged parathyroid glands (≥ 5 mm).
• Sestamibi (Tc‑99m) scan: Functional imaging to confirm hyperfunctioning tissue.
• 4‑D CT or MRI: Used when ultrasound is inconclusive or for ectopic glands.
• Bone densitometry (DXA): To quantify osteoporosis.
• Renal imaging (CT/ultrasound): Detect stones or nephrocalcinosis.

Genetic Testing

Once biochemical and imaging findings suggest PHPT, targeted genetic panels (including CYP24A1, MEN1, CDC73) confirm QTHP. Testing is recommended for:

• Patients with a family history of early‑onset PHPT.
• Individuals with hypercalcemia plus low 25‑OH vitamin D and high 1,25‑OH₂.
• Anyone undergoing parathyroid surgery where the phenotype is atypical.

Differential Diagnosis

Rule out secondary causes (e.g., malignancy‑associated PTH‑related peptide, vitamin D intoxication, sarcoidosis) and other genetic syndromes (MEN2A, hyperparathyroidism‑jaw tumor syndrome).

Treatment Options

The therapeutic goal is to normalize calcium and PTH levels, protect bone and renal health, and improve quality of life.

Medical Management

• Hydration: Adequate oral fluids (2–3 L/day) reduce calcium concentration and promote renal excretion.
• Bisphosphonates (e.g., alendronate): Useful for osteoporosis; they inhibit bone resorption.
• Calcimimetics (cinacalcet): Increase the sensitivity of the calcium‑sensing receptor, lowering PTH secretion. Often used when surgery is contraindicated or as bridge therapy.<sup>[4]</sup>
• Vitamin D management: Avoid high‑dose supplementation; give low‑dose calcifediol only under specialist supervision.
• Loop diuretics (e.g., furosemide): May be added in acute hypercalcemia after volume repletion.

Surgical Intervention

Parathyroidectomy remains the definitive cure for most QTHP patients.

• Focused minimally invasive parathyroidectomy: Guided by intra‑operative PTH monitoring; high cure rates (> 95 %).
• Bilateral neck exploration: Reserved for multigland disease or when pre‑op imaging is equivocal.
• Subtotal parathyroidectomy or auto‑transplantation: Considered when hyperplasia involves all glands.

Post‑operative hypocalcemia (hungry bone syndrome) is more common in QTHP due to rapid bone remineralization; calcium and vitamin D supplementation are required temporarily.

Lifestyle & Supportive Measures

• Limit calcium intake to 800–1,000 mg/day (unless prescribed higher by a physician).
• Maintain adequate magnesium (300–400 mg/day) as low Mg can worsen PTH secretion.
• Engage in weight‑bearing exercise 3–5 times weekly to protect bone density.
• Avoid excessive vitamin D supplementation (> 1,000 IU/day) without monitoring.
• Regular monitoring: calcium, PTH, renal function every 3–6 months after treatment.

Living with Quintana‑type Hyperparathyroidism

Long‑term management focuses on surveillance, symptom control, and lifestyle balance.

Daily Management Tips

• Hydration: Keep a water bottle handy; aim for clear‑yellow urine.
• Diet: Favor leafy greens, nuts, and fish; reduce processed foods high in sodium and oxalate (spinach, nuts) to lower stone risk.
• Medication adherence: Use a weekly pill organizer for calcimimetics or bisphosphonates.
• Bone health monitoring: Repeat DXA every 1–2 years; discuss pharmacologic bone protectors with your doctor.
• Kidney watch: Annual renal ultrasound if you have a history of stones.
• Family screening: Encourage first‑degree relatives to undergo genetic testing and calcium screening.

Psychosocial Considerations

Living with a rare genetic condition can cause anxiety. Connecting with patient support groups (e.g., Hyperparathyroidism Association) and accessing counseling services can improve mental well‑being.

Prevention

Because QTHP is genetically predetermined, primary prevention is not possible. However, secondary prevention—delaying disease onset or reducing severity—can be achieved by modifying known risk factors.

• Screen at‑risk relatives early: Baseline calcium/PTH testing at age 18‑20, then every 2–3 years.
• Moderate calcium and vitamin D intake: Follow physician‑directed recommendations.
• Avoid chronic lithium therapy unless essential.
• Stay active and maintain a healthy weight to preserve bone mass.

Complications

If left untreated, persistent hypercalcemia can lead to serious, sometimes irreversible, sequelae.

• Severe osteoporosis and fractures: Up to 40 % develop fragility fractures.
• Nephrolithiasis & chronic kidney disease: Recurrent stones can cause renal scarring; CKD prevalence in QTHP patients is ~12 %.<sup>[5]</sup>
• Cardiovascular disease: Hypercalcemia is associated with hypertension, arrhythmias, and accelerated atherosclerosis.
• Neurocognitive decline: Chronic elevated calcium may impair memory and mood.
• Pancreatitis: Rare but potentially life‑threatening.

When to Seek Emergency Care

---

Sources:
[1] National Institutes of Health – Genetics of Primary Hyperparathyroidism, 2022.
[2] Mayo Clinic. Primary hyperparathyroidism fact sheet, 2023.
[3] Khosla S, et al. “Kidney stone prevalence in hyperparathyroidism,” *J Clin Endocrinol Metab*, 2021.
[4] FDA‑label information for cinacalcet (Sensipar), 2023.
[5] WHO Chronic Kidney Disease Report, 2022.

```